The recent failure of Pfizer’s late-stage trial for Duchenne muscular dystrophy (DMD) gene therapy marks a significant setback for patients but opens the door for competitors like Sarepta Therapeutics. Pfizer’s gene therapy did not improve motor function in young boys and follows a similar setback for Sarepta’s Elevidys. Despite this, Sarepta remains optimistic, citing positive secondary outcomes and ongoing FDA support. As the biotech landscape evolves, Symphony Benefits Solution is positioned to be a steadfast resource in the gene and cell therapy space, offering the latest insights and support for advancements in these critical therapies. Stay informed with Symphony Benefits Solution for all your gene therapy updates and needs.
What a great company making an impact with employers and changing lives. Renalogic is operated by people who care and work to find the right answers.
Broker-Partner
Renalogic and its cost containment methodology decreased that first dialysis claim to $120,000, and it didn’t even hit their Stop-Loss policy. It was a home run for everybody.
Broker-Partner
Having this program and having a nurse reach out to check on me, see how I was doing, and if there's anything I needed or that they could do for me, has made a HUGE difference for me and I know it makes a difference for all the other patients that are lucky enough to have it.
56 y/o Survivor Diagnosed with Bladder Cancer
Thanks to Renalogic for their unwavering support and guidance. I have made tremendous progress in my weight loss goals, as I am now down to 147 lbs. The dedicated nurses at Renalogic have been with me every step of the way, providing encouragement and celebrating my achievements. I am grateful for the support and motivation from my nurses along the way. They have applauded my efforts in making healthier choices, such as avoiding fast food and reducing my sodium intake. These lifestyle changes have contributed to my continuous progress.
I’m not sure what I would have done without your help. You arranged for a second opinion at a hospital I didn’t even realize I could go to and they recommended a totally different treatment. I have no way to thank you for possibly saving my life.
49 y/o Survivor Diagnosed with Renal Cell Carcinoma
We have been working with Interlink for over fifteen years utilizing their Transplant COE. We greatly value their staff expertise, support, and flexibility. Several of our self-funded clients are in a market that had historically directed transplants to facilities that were close geographically, but prohibitively expensive. Interlink was able to provide concise and specific outcomes and cost data to illustrate that an alternative facility in a location just a little further away made much more sense. Without the outcomes data, we could not have convinced members and providers to re-evaluate and re-direct to more cost effective facilities which provide transplant patients with documented better outcomes. Interlink has been a strategic partner to us and our clients in this critical area of health plan management.
Senior Vice President, Lockton Companies
Get Updates And Stay Connected -Subscribe To Our Newsletter
Symphony Benefits Solution delivers comprehensive healthcare benefit platforms, specializing in transplant, cancer, ESRD, and gene & cell therapy, ensuring exceptional patient outcomes through cutting-edge care and expertise.
Contact Information
- (615)535-1830
- info@thesymphonyprogram.com
-
4660 NE Belknap Court, Suite 209
Hillsboro, Oregon 97124